FLT3 ligand in acute myeloid leukemia: a simple test with deep implications

References

• Lyman SD, James L, Vanden Bos T, et al. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell. 1993;75(6):1157–1167.
   PubMed Web of Science ®Google Scholar
• Tsapogas P, Mooney CJ, Brown G, et al. The cytokine Flt3-ligand in normal and malignant hematopoiesis. Int J Mol Sci. 2017;18(6):1115.
   Web of Science ®Google Scholar
• McClanahan T, Culpepper J, Campbell D, et al. Biochemical and genetic characterization of multiple splice variants of the Flt3 ligand. Blood. 1996;88(9):3371–3382.
   PubMed Web of Science ®Google Scholar
• Bertho JM, Demarquay C, Frick J, et al. Level of Flt3-ligand in plasma: a possible new bio-indicator for radiation-induced aplasia. Int J Radiat Biol. 2001;77(6):703–712.
   PubMed Web of Science ®Google Scholar
• Wodnar-Filipowicz A, Lyman SD, Gratwohl A, et al. Flt3 ligand level reflects hematopoietic progenitor cell function in aplastic anemia and chemotherapy-induced bone marrow aplasia. Blood. 1996;88(12):4493–4499.
   PubMed Web of Science ®Google Scholar
• Drexler HG, Quentmeier H. Mini ReviewFLT3: receptor and ligand. Growth Factors. 2004;22(2):71–73.
   PubMed Web of Science ®Google Scholar
• Matthews W, Jordan CT, Wiegand GW, et al. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell. 1991;65(7):1143–1152.
   PubMed Web of Science ®Google Scholar
• Kazi JU, Rönnstrand L. The role of SRC family kinases in FLT3 signaling. Int J Biochem Cell Biol. 2019;107:32–37.
   PubMed Web of Science ®Google Scholar
• Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100(5):1532–1542.
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
   PubMed Web of Science ®Google Scholar
• Kuchenbauer F, Kern W, Schoch C, et al. Detailed analysis of FLT3 expression levels in acute myeloid leukemia. Haematologica. 2005;90:1617–1625.
   PubMed Web of Science ®Google Scholar
• Dehmel U, Zaborski M, Meierhoff G, et al. Effects of FLT3 ligand on human leukemia cells. I. Proliferative response of myeloid leukemia cells. Leukemia. 1996;10(2):261–270.
   PubMed Web of Science ®Google Scholar
• Meierhoff G, Dehmel U, Gruss HJ, et al. Expression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines. Leukemia. 1995;9(8):1368–1372.
   PubMed Web of Science ®Google Scholar
• Brasel K, Escobar S, Anderberg R, et al. Expression of the flt3 receptor and its ligand on hematopoietic cells. Leukemia. 1995;9(7):1212–1218.
   PubMed Web of Science ®Google Scholar
• Drexler HG. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia. 1996;10(4):588–599.
   PubMed Web of Science ®Google Scholar
• Zheng R, Levis M, Piloto O, et al. FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. Blood. 2004;103(1):267–274.
   PubMed Web of Science ®Google Scholar
• Weisel KC, Yildirim S, Schweikle E, et al. Regulation of FLT3 and its ligand in normal hematopoietic progenitor cells. Ann Hematol. 2009;88(3):203–211.
   PubMed Web of Science ®Google Scholar
• Hawley TS, Fong AZ, Griesser H, et al. Leukemic predisposition of mice transplanted with gene-modified hematopoietic precursors expressing flt3 ligand. Blood. 1998;92(6):2003–2011.
   PubMed Web of Science ®Google Scholar
• Bruserud Ø, Hovland R, Wergeland L, et al. Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities. Haematologica. 2003;88(4):416–428.
   PubMed Web of Science ®Google Scholar
• McKenna HJ, Smith FO, Brasel K, et al. Effects of flt3 ligand on acute myeloid and lymphocytic leukemic blast cells from children. Exp Hematol. 1996;24(2):378–385.
   PubMed Web of Science ®Google Scholar
• Murohashi I, Yoshida K, Kishimoto K, et al. Differential response to stem cell factor and Flt3 ligand by the FAB subtype in acute myeloid leukemia clonogenic cells. J Interferon Cytokine Res. 2002;22(3):335–341.
   PubMed Web of Science ®Google Scholar
• Lisovsky M, Estrov Z, Zhang X, et al. Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax. Blood. 1996;88(10):3987–3997.
   PubMed Web of Science ®Google Scholar
• Meyer C, Drexler HG. FLT3 ligand inhibits apoptosis and promotes survival of myeloid leukemia cell lines. Leuk Lymphoma. 1999;32(5-6):577–581.
   PubMed Web of Science ®Google Scholar
• Demmerath E-M, Bohler S, Kunze M, et al. In vitro and in vivo evaluation of possible pro-survival activities of PGE2, EGF, TPO and FLT3L on human hematopoiesis. Haematologica. 2019;104(4):669–677.
   PubMed Web of Science ®Google Scholar
• Dehmel U, Quentmeier H, Drexler HG. Effects of FLT3 ligand on human leukemia cells. II. Agonistic and antagonistic effects of other cytokines. Leukemia. 1996;10(2):271–278.
   PubMed Web of Science ®Google Scholar
• Piacibello W, Fubini L, Sanavio F, et al. Effects of human FLT3 ligand on myeloid leukemia cell growth: heterogeneity in response and synergy with other hematopoietic growth factors. Blood. 1995;86(11):4105–4114.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. [Cited 2020 Oct 20]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf.
   Google Scholar
• Daver N, Schlenk RF, Russell NH, et al. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33(2):299–312.
   PubMed Web of Science ®Google Scholar
• Yang X, Sexauer A, Levis M. Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase. Br J Haematol. 2014;164(1):61–72.
   PubMed Web of Science ®Google Scholar
• Sato T, Yang X, Knapper S, et al. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood. 2011;117(12):3286–3293.
   PubMed Web of Science ®Google Scholar
• Chen F, Ishikawa Y, Akashi A, et al. Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells. Oncotarget. 2016;7(30):47018–47032.
   PubMed Web of Science ®Google Scholar
• Wang A, Wu H, Chen C, et al. Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML. Oncotarget. 2016;7(20):29131–29142.
   PubMedGoogle Scholar
• Zheng R, Bailey E, Nguyen B, et al. Further activation of FLT3 mutants by FLT3 ligand. Oncogene. 2011;30(38):4004–4014.
   PubMed Web of Science ®Google Scholar
• Kharazi S, Mead AJ, Mansour A, et al. Impact of gene dosage, loss of wild-type allele, and FLT3 ligand on Flt3-ITD-induced myeloproliferation. Blood. 2011;118(13):3613–3621.
   PubMed Web of Science ®Google Scholar
• Kawase T, Nakazawa T, Eguchi T, et al. Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells. Oncotarget. 2019;10(58):6111–6123.
   PubMedGoogle Scholar
• Bruserud O, Foss B, Petersen H. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L). Eur Cytokine Netw. 2001;12(2):231–238.
   PubMed Web of Science ®Google Scholar
• Prat M, Frick J, Laporte J-P, et al. Kinetics of plasma FLT3 ligand concentration in hematopoietic stem cell transplanted patients. Leuk Lymphoma. 2006;47(1):77–80.
   PubMed Web of Science ®Google Scholar
• Haidar JH, Bazarbachi A, Mahfouz R, et al. Serum Flt3 ligand variation as a predictive indicator of hematopoietic stem cell mobilization. J Hematother Stem Cell Res. 2002;11(3):533–538.
   PubMedGoogle Scholar
• Şahin M, Haznedaroğlu İC, Özbalcı D. Peripheral FLT-3 ligand levels as a pathobiological parameter duringthe clinical course of acute myeloid leukemia. Turk J Med Sci. 2016;46(6):1889–1893.
   PubMed Web of Science ®Google Scholar
• Chevallier P, Eugene T, Robillard N, et al. (90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study. Lancet Haematol. 2015;2(3):e108–e117.
   PubMed Web of Science ®Google Scholar
• Peterlin P, Gaschet J, Guillaume T, et al. FLT3 ligand plasma levels in acute myeloid leukemia. Haematologica. 2019;104(6):e240–e243.
   PubMed Web of Science ®Google Scholar
• Milne P, Wilhelm-Benartzi C, Grunwald MR, et al. Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia. Blood Adv. 2019;3(20):3052–3061.
   PubMed Web of Science ®Google Scholar
• Dickinson RE, Milne P, Jardine L, et al. The evolution of cellular deficiency in GATA2 mutation. Blood. 2014;123(6):863–874.
   PubMed Web of Science ®Google Scholar
• Liu Y, Huang H, Chen Z, et al. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity. J Gene Med. 2003;5(8):668–680.
   PubMed Web of Science ®Google Scholar
• Woiciechowsky A, Regn S, Kolb HJ, et al. Leukemic dendritic cells generated in the presence of FLT3 ligand have the capacity to stimulate an autologous leukemia-specific cytotoxic T cell response from patients with acute myeloid leukemia. Leukemia. 2001;15(2):246–255.
   PubMed Web of Science ®Google Scholar
• Pawlowska AB, Hashino S, McKenna H, et al. In vitro tumor-pulsed or in vivo Flt3 ligand-generated dendritic cells provide protection against acute myelogenous leukemia in nontransplanted or syngeneic bone marrow-transplanted mice. Blood. 2001;97(5):1474–1482.
   PubMed Web of Science ®Google Scholar
• Lyman SD, Seaberg M, Hanna R, et al. Plasma/serum levels of flt3 ligand are low in normal individuals and highly elevated in patients with Fanconi anemia and acquired aplastic anemia. Blood. 1995;86(11):4091–4096.
   PubMed Web of Science ®Google Scholar
• Molyneux G, Gibson FM, Whayman M, et al. Serum FLT-3 ligand in a busulphan-induced model of chronic bone marrow hypoplasia in the female CD-1 mouse. Int J Exp Pathol. 2008;89(2):159–170.
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey EH, Amadori S, European LeukemiaNet, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453–474.
   PubMed Web of Science ®Google Scholar
• Peterlin P, Gaschet J, Guillaume T, et al. FLT3 ligand plasma levels have no impact on outcomes after allotransplant in acute leukemia. Cytokine. 2019;120:85–87.
   PubMed Web of Science ®Google Scholar